Virus injection takes on tough tumors in early trial
NCT ID NCT06368921
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests a modified virus called VRT106, which is injected directly into tumors to kill cancer cells. It involves 30 adults with advanced solid tumors that haven't responded to standard treatments. The main goal is to check safety and find the best dose, while also looking at how the virus spreads and whether it helps fight the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VRT106 (a modified virus that targets and kills cancer cells)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors that haven't responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 30 participants, so safety and dosing are still being figured out. It may not shrink tumors or work for everyone, and there could be side effects from the virus or injection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Affiliated Cancer Hospital of Shandong First Medical University
RECRUITINGJinan, Shandong, China
Contact
-
Affiliated Cancer Hospital of Zhengzhou University
RECRUITINGZhengzhou, Henan, China
Contact
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, China
Contact Email: •••••@•••••